An application made for this job — a tailored resume and cover letter that speak straight to the posting.
AstraZeneca Oncology R&D in Amsterdam is hiring a Scientist Chemistry (Bachelor/Master) to join the Medicinal Chemistry team. You will synthesize and analyze new molecules, driving lab progress and contributing to projects advancing toward clinical development.
The role includes scaling syntheses to support in vivo testing, presenting results in meetings, and collaborating across teams. MSc or equivalent with 3+ years in organic/medicinal chemistry is preferred; English fluency required.
Developing future oncology medicines through hands-on medicinal chemistry.
Within our Medicinal Chemistry department, we have exciting opportunities for Scientists Chemistry, who are enthusiastic about hands-on laboratory work and enjoy working closely with colleagues in a collaborative environment. These roles offer the chance to apply yourexpertise, and to make a real impact on the progress of our projects.
AcertaPharma will berelocatingtoAmsterdam, with the current move planned forMarch/April 2027. Until that time, you will be working from our facilities in Oss. After the move, you will be basedatournew sitein Amsterdam.
Our preference is for the new Senior Scientist to join in January 2027; however, we can be flexible on the starting date depending on your availability.
ScientistChemistry (bachelor/master)5X
Pivot Park Oss|AmsterdamUMC campus
Fulltime
Your challenge:
AsaScientist,you willbepart of ourMedicinal Chemistry teamand focus on thesynthesis and analysis of new molecules.You will be the driving force in the lab,contributing to theprogressof our projects towards clinical development.
What will you be doing?
Whatareyoubringing?
What do we offer you?
About AstraZeneca Oncology R&D, Amsterdam
At AstraZeneca Amsterdam, we bring together two research groups, in haemato-oncology and next-generation cell therapy research. Together, they form our OncologyR&D hub in the Netherlands, working closely with colleagues in the US, Canada,Spainand the UK, to develop innovative treatments for patients with cancer.
Our haematology R&D group was bornas AcertaPharma, one of the Netherland’s greatest biotech success stories. Its small-molecule BTK inhibitor has been approved by both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of Chronic LymphocyticLeukaemia(CLL) and Mantle Cell Lymphoma (MCL). In Amsterdam approximately 100 colleagues continue the development of new therapies forhaematologicalmalignancies under the AstraZeneca brand name.
AstraZeneca’s Cell Therapy R&D team focuses on developing next-generation T-cell receptor (TCR) therapies targeting neoantigens in solidtumours. With a team of around 75 scientists, we work on both fullyindividualizedand shared neo-antigen approaches, with the aim of improving outcomes for patients with cancer.
Our oncology research and development hub is anchored by our newstate-of-the-artlaboratoriesinOne Helixand the adjacent Plus Ultra Amsterdam building, bothlocatedon the Amsterdam University Medical Centre (Amsterdam UMC) campus. Our hub is firmly positioned at the heart of the Dutch research community network, creating new opportunities for our people, our science, and the patients we work to transform outcomes for.
We don’t work with a fixed closing date: The vacancy will remain online until we have concluded the process.
Date Posted
02-okt.-2026
Closing Date
22-nov.-2026
AstraZeneca embraces diversity and equality of opportunity. We are committed to building an inclusive and diverse team representing all backgrounds, with as wide a range of perspectives as possible, and harnessing industry-leading skills. We believe that the more inclusive we are, the better our work will be. We welcome and consider applications to join our team from all qualified candidates, regardless of their characteristics. We comply with all applicable laws and regulations on non-discrimination in employment (and recruitment), as well as work authorization and employment eligibility verification requirements.